| [1] Burton D R, Rafi A, Dan H B, et al. A blueprint for HIV vaccine discovery. Cell Host Microbe, 2012,12(4): 396-407.
[2] Robb M L, Supachai R N, Sorachai N, et al. Risk behaviour and time as covariates for efficacy of the HIV-1 vaccine regimen ALVAC-HIV (vCP1521) and AIDSVAX B/E: a post-hoc analysis of the Thai phase 3 efficacy trial RV 144. Lancet Infect Dis, 2012, 12(7): 531-537.
[3] Thomas J H. To neutralize or not, a key HIV vaccine question. Nature, 2011, 17(10): 1195-1197.
[4] Johnston M I, Fauci A S. HIV-1 vaccine development—improving on natural immunity. N Engl J Med, 2011, 365(10): 873-875.
[5] Dereuddre-Bosquet N. MiniCD4 microbicide prevents HIV infection of human mucosal explants and vaginal transmission of SHIV162P3 in cynomolgus macaques. PLoS Pathogens, 2012, 8(12): e1003071.
[6] Preston N, Theresa K, Thomas N, et al. A topical microbicide Gel formulation of CCR5 antagonist maraviroc prevents HIV-1 vaginal transmission in humanized RAG-hu mice. Plus One, 2011,6(6):e20209.
[7] Huskens D, Schols D. Algal lectins as potential HIV microbicide candidates . Mar Drugs, 2012, 10(7):1476-1497.
[8] Craig B W , John C T, Robert W D. HIV: Cell binding and entry. Cold Spring Harb Perspect Med, 2012, 2:a006866.
[9] Berger E A. A new classification for HIV-1. Nature, 1998,391(6664): 240.
[10] Hogan C M, Hammer S M. Host determinants in HIV infection and disease. Part 2: genetic factors and implications for antiretroviral therapeutics. Ann Intern Med, 2001, 134: 978-996.
[11] Clerici M, Butto S, Lukwiya M, et al. Immune activation in Africa is environmentally-driven and is associated with upregulation of CCR5. Italian-Ugandan AIDS Project Aids, 2000, 14: 2083-2092.
[12] Quillent C, Oberlin E, Braun J, et al. HIV-1-resistance phenotype conferred by combination of two separate inherited mutations of CCR5 gene. Lancet, 1998, 351, 14-18.
[13] Cocchi F, DeVico A L, Garzino D, et al. Identification of RANTES, MIP-1 alpha, and MIP-1beta as the major HIV-1-suppressive factors produced by CD8+ T cells . Science, 1995, 270(5243):1811-1815.
[14] Doms R W. Fusing HIV and chemokine receptors. J Immunol, 2011, 186(11): 6073-6075.
[15] Skelton N J, Schall T J. NMR assignments and solution conformation of RANTES, a chemokine of the C-C type. Biol Chem, 1995,34(16):5329-5342.
[16] Chung C W, Cooke R M, Proudfoot A E, et al. The three-dimensional solution structure of RANTES. BiolChem, 1995, 34(29):9307-9414.
[17] Czaplewski L G, McKeating J. Identification of amino acid residues critical for aggregation of human CC chemokines macrophage inflammatory protein (MIP)-1alhpa,MIP-1beta, and RANTES, Characterization of active disaggregated chemokine variant. Biol Chem, 1999, 274 (23):16077-16084.
[18] Mysinger M M. Structure-based ligand discovery for the protein-protein interface of chemokine receptor CXCR4. Proc Natl Acad Sci U S A, 2012, 109(14): 5517-5522.
[19] Munoz L M. Chemokine receptor oligomerization: a further step toward chemokine function. Immunology Letters, 2012, 145(1-2): 23-29.
[20] Duma L, Haussinger D, Rogowski, et al. Recognition of RANTES by extracellular parts of the CCR5 receptor. Journal of Molecular Biology, 2007, 365 (4):1063-1075.
[21] Huang C C, Lam S N, Acharya P, et al. Structures of the CCR5 N terminus and of a tyrosine-sulfated antibody with HIV-1-1 gp120 and CD4. Science, 2007, 317 (5846):1930-1934.
[22] Jin H, Shen X, Baggett B R, et al. The human CC chemokine MIP-1beta dimer is not competent to bind to the CCR5 receptor. Journal of Biochemistry, 2007,282 (38): 27976-27983.
[23] Wang J, Michael N. Dimerization of chemokine receptors in living cells: key to receptor function and novel targets for therapy. Drug Discovery Today, 2008, 13:625-632.
[24] Baker A M, Sauliere A, Gaibelet G, et al. CD4 interacts constitutively with multiple CCR5 at the plasma membrane of living cells. The Journal of Biological Chemistry, 2007, 282(48): 35163-35168.
[25] Angelika R, Barbara B, Elena G ,et al. A biophysica insight into the RANTES—glycosaminoglycan interaction. Biochimica et Biophysica Acta, 2009, 1794:577-582.
[26] Martin L, Blanpain C, Garnier P, et al. Structural and functional analysis of the RANTES-glycosaminoglycans interactions. Biochemistry, 2001, 40(21): 6303-6318.
[27] McCornack M, Boren D M, Li Wang P J. Glycosaminoglycan disaccharide alters the dimer dissociation constant of the chemokine MIP-1 beta. Biochemistry, 2004, 43 (31) :10090-10101.
[28] Proudfoot A E, Handel T M, Johnson Z, et al. Glycosaminoglycan binding and oligomerization are essential for the in vivo activity of certain chemokines. Proc Natl Acad Sci U S A, 2003,100(4):1885-1890.
[29] Paavola C D, Hemmerich S, Grunberger D, et al. Monomeric monocyte chemoattractant protein-1 (MCP-1) binds and activates the MCP-1 receptorCCR2B. The Journal of Biological Chemistry, 1998, 273(50): 33157-33165.
[30] Oliver H , Karim D , Danielle P, et al. Human immune- deficiency virus type1 entry inhibitors selected on living cells from a library of Phage Chemokines . Journal of Virology, 2003, 7: 6637-6644.
[31] Jin H, Ioannis K, Li P, et al. Structural and functional studies of potent anti-HIV chemokine variant P2-RANTES. Proteins , 2010, 78:295-308.
[32] Grone H J. Met-RANTES reduces vascular and tubular damage during acute renal transplant rejection: blocking monocyte arrest and recruitment. FASEB J, 1999, 13 (11): 1371-1383.
[33] Simmons G, Clapham P R, Picard L, et al. Potent inhibition of HIV-1 infectivity in macrophages and lymphocytes by a novel CCR5 antagonist. Science, 1997, 276 (5310) :276-279.
[34] Mosier D E, Picchio G R, Gulizia R J, et al. Highly potent RANTES analogues either prevent CCR5-using human immunodeficiency virus type 1 infection in vivo or rapidly select for CXCR4-using variants. Journal of Virology ,1999,73(5):3544-3450.
[35] Hartley O, Gaertner H, Wilken J, et al. Medicinal chemistry applied to a synthetic protein:development of highly potent HIV-1 entry inhibitors . PNAS 2004,101 (47):16460-16465.
[36] Lederman M M, Veazey R S, Offord R, et al. Prevention of vaginal SHIV-1 transmission in Rhesus macaques through inhibition of CCR5. Science, 2004, 306 (5695) :485-487.
[37] Oravecz T, Pall M, Roderiquez G, et al. Regulation of the receptor specificity and function of the chemokine RANTES by dipeptidyl peptidase IV (CD26)-mediated cleavage. J Exp Med, 1997, 186(11):1865-1872.
[38] Arenzana S F, Virelizier J L, Rousset D, et al. HIV blocked by chemokine antagonist. Nature, 1996, 383(6599):400.
[39] Polo S. Enhancement of the HIV-1-1 inhibitory activity of RANTES by modification of the N-terminal region: dissociation from CCR5 activation. European Journal of Immunology , 2000, 30(11): 3190-3198.
[40] Samson M, LaRosa G, Libert F, et al. The second extracellular loop of CCR5 is the major determinant of ligand specificity. Journal of Biological Chemisry, 1997, 272(40) :24934-24941.
[41] Salanga, C L, Handel T M. Chemokine oligomerization and interactions with receptors and glycosaminoglycans: The role of structural dynamics in function. Experimental Cell Research, 2011. 317(5): 590-601.
[42] Kobilka B K, Deupi X. Conformational complexity of G-protein-coupled receptors . Trends in Pharmacological Science, 2007, 28(8): 397-406.
[43] Vangelista L, Longhi R, Sironi F, et al. Critical role of the N-loop and beta1-strand hydrophobic clusters of RANTES-derived peptides in anti-HIV activity. Biochemical and Biophysical Research Communications, 2006,351(3):664-668.
[44] Lusso P. Molecular engineering of RANTES peptide mimetic with potent anti-HIV-1 activity. FASEB J, 2011, 25(4): 1230-1243.
[45] Michael C. HIV Envelop: Challenges and opportunities for development of entry inhibitors. Trends in Microbiology, 2011, 19(4): 191-197.
[46] Anastassopoulou C G .Resistance of a human immunodeficiency virus type 1 isolate to a small molecule CCR5 inhibitor can involve sequence changes in both gp120 and gp41. Virology, 2011, 413(1): 47-59.
[47] Schellenberg J J, Plummer F A. The microbiological context of HIV-1 resistance: vaginal microbiota and mucosal inflammation at the viral point of entry. International Journal of Inflammation, 2012, 2012: 131243.
[48] Vangelista L, Massimiliano S, Liu X, et al., Engineering of Lactobacillus jensenii to secrete RANTES and a CCR5 antagonist analogue as live HIV-1 blockers. Antimicrobial Agents and Chemotherapy, 2010, l54(7): 2994-3001.
[49] Balkus J E, Mitchell C, Agnew, et al. Detection of hydrogen peroxide-producing Lactobacillus species in the vagina: a comparison of culture and quantitative PCR among HIV-1 seropositive women. BMC Infectious Disease, 2012,12: 188.
[50] Liu X, Lagenaur L A, Simpson D A, et al. Engineered vaginal lactobacillus strain for mucosal delivery of the human immunodeficiency virus inhibitor cyanovirin-N. Antimicrob. Agents Chemother, 2006, 50(10):3250-3259.
[51] Nishiyama Y, Murakami T Shikama. Anti-HIV-1 peptides derived from partial amino acid sequences of CC-chemokine RANTES. Regulated upon activation, normal T-cell expressed and secreted. Bioorganic & Medicinal Chemistry Letters, 2002, 10(12):4113-4117.
[52] Ramnarine E J, Devico A L, Vigil-Cruz S C. Analogues of N-terminal truncated synthetic peptide fragments derived from RANTES inhibitHIV-1-1 infectivity. Bioorganic & Medicinal Chemistry Letters, 2006, 16(1):93-95.
[53] Mack M, Pfirstinger J Haas. Preferential targeting of CD4-CCR5 complexes with bifunctional inhibitors: a novel approach to block HIV-1-1 infection. Journal of Immunology, 2005, 175(11):7586-7593. |
